Nanocan Therapeutics

Investors · 2

AC

ACADEMY INVESTORArlington

AI

AIN VenturesNew York · $500K – $1M

$6.2M disclosed across 2 rounds · 2020–2022

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

NA

Nanobiotix7 shared keywordsNanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients. The company builds on French scientific research and targets patients worldwide through disruptive treatment approaches.

IN

Integrated Nanotherapeutics Inc.6 shared keywordsIntegrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.

TR

Transcode Therapeutics5 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.

NA

Nanobots Therapeutics4 shared keywordsNanobots Therapeutics develops the MotionTx platform to create nanobots that penetrate tissues and enhance drug accumulation in target cells for therapeutic applications. The company is a spin-off of ICREA and IBEC resulting from research by Prof. Samuel Sánchez.

Companies competing with Nanocan Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.